Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic octreotide to prevent diarrhoea in patients receiving lapatinib + capecitabine for metastatic breast cancer
2014-000256-28Phase 2Completed
- Sponsor
- GSK
- Start
- May 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of octreotide in breast cancer and diarrhea (2 arms), sponsored by GSK. Primary endpoint: Proportion of subjects experiencing diarrhoea grade ≥2. Started May 2014; status: completed.
02
Drugs
octreotide
03
Conditions
breast cancerdiarrhea
Beyond the preview
Go deeper on 2014-000256-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000256-28.